SpringWorks Therapeutics (NASDAQ:SWTX) Shares Acquired by GAMMA Investing LLC

GAMMA Investing LLC increased its holdings in SpringWorks Therapeutics (NASDAQ:SWTX - Free Report) by 13,138.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,371 shares of the company's stock after purchasing an additional 13,270 shares during the period. GAMMA Investing LLC's holdings in SpringWorks Therapeutics were worth $590,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in SWTX. Vanguard Group Inc. boosted its holdings in SpringWorks Therapeutics by 6.6% in the fourth quarter. Vanguard Group Inc. now owns 7,158,871 shares of the company's stock valued at $258,650,000 after acquiring an additional 445,593 shares during the last quarter. Boxer Capital Management LLC acquired a new position in SpringWorks Therapeutics in the fourth quarter valued at $123,620,000. Pictet Asset Management Holding SA boosted its holdings in SpringWorks Therapeutics by 24.2% in the fourth quarter. Pictet Asset Management Holding SA now owns 2,391,412 shares of the company's stock valued at $86,402,000 after acquiring an additional 465,494 shares during the last quarter. Capital International Investors boosted its holdings in SpringWorks Therapeutics by 92.7% in the fourth quarter. Capital International Investors now owns 2,361,746 shares of the company's stock valued at $85,330,000 after acquiring an additional 1,136,079 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC boosted its holdings in SpringWorks Therapeutics by 0.5% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 1,499,134 shares of the company's stock valued at $54,164,000 after acquiring an additional 7,072 shares during the last quarter.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. HC Wainwright reiterated a "neutral" rating and issued a $47.00 target price (down previously from $74.00) on shares of SpringWorks Therapeutics in a report on Wednesday, April 30th. Evercore ISI cut SpringWorks Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, April 28th. Guggenheim reiterated a "neutral" rating and issued a $47.00 target price on shares of SpringWorks Therapeutics in a report on Monday, May 12th. TD Cowen reiterated a "hold" rating and issued a $47.00 target price (down previously from $66.00) on shares of SpringWorks Therapeutics in a report on Tuesday, April 29th. Finally, Barclays reiterated an "equal weight" rating and issued a $47.00 target price (down previously from $63.00) on shares of SpringWorks Therapeutics in a report on Monday, April 28th. Seven analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, SpringWorks Therapeutics presently has an average rating of "Hold" and a consensus target price of $52.57.

SpringWorks Therapeutics Trading Up 0.4%

Shares of SWTX traded up $0.18 during midday trading on Friday, reaching $46.96. 10,429,315 shares of the company were exchanged, compared to its average volume of 2,482,989. The stock has a 50-day moving average price of $45.13 and a 200-day moving average price of $44.00. The company has a market cap of $3.54 billion, a price-to-earnings ratio of -13.77 and a beta of 0.70. SpringWorks Therapeutics has a 1-year low of $28.21 and a 1-year high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last issued its quarterly earnings data on Friday, May 9th. The company reported ($1.11) EPS for the quarter, missing analysts' consensus estimates of ($0.81) by ($0.30). The company had revenue of $49.09 million for the quarter, compared to analyst estimates of $64.19 million. SpringWorks Therapeutics had a negative return on equity of 51.10% and a negative net margin of 115.60%. Equities research analysts anticipate that SpringWorks Therapeutics will post -2.05 earnings per share for the current year.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.